Education
About Us
Working with TipRanks
Follow Us
Kineta (KANT)
OTHER OTC:KANT
KANT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.18 - $1.15
Previous CloseN/A
Volume280.00
Average Volume (3M)18.68K
Market Cap
$4.55M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)629.00K
Price to Earnings (P/E)―
Beta0.18
Next Earnings
May 08, 2025EPS EstimateN/A
Last Dividend Ex-Date
Dec 19, 2022Dividend YieldN/A
Share Statistics
EPS (TTM)-1.43
Shares Outstanding51,099,000
10 Day Avg. Volume12,197
30 Day Avg. Volume18,685
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Kineta News
PremiumCompany Announcements
TuHURA Biosciences Completes Acquisition of Kineta
PremiumCompany Announcements
Kineta Approves Merger with TuHURA Biosciences
PremiumCompany Announcements
Kineta and TuHURA Biosciences Announce Merger Agreement
PremiumCompany Announcements
Kineta Amends Merger Agreement with TuHURA Biosciences
PremiumCompany Announcements
Kineta Merges with TuHURA to Enhance Cancer Treatment
Options Prices
Currently, No data available
---
Ownership Overview
19.85% Insiders
<0.01% Mutual Funds
3.04% Other Institutional Investors
77.11% Public Companies and
Individual Investors
KANT FAQ
What was Kineta’s price range in the past 12 months?
Kineta lowest stock price was $0.18 and its highest was $1.15 in the past 12 months.
What is Kineta’s market cap?
Kineta’s market cap is $4.55M.
When is Kineta’s upcoming earnings report date?
Kineta’s upcoming earnings report date is May 08, 2025 which is 58 days ago.
How were Kineta’s earnings last quarter?
Kineta released its earnings results on Mar 28, 2025. The company reported -$0.204 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.204.
Is Kineta overvalued?
According to Wall Street analysts Kineta’s price is currently Overvalued.
Does Kineta pay dividends?
Kineta pays a Notavailable dividend of $1.429 which represents an annual dividend yield of N/A. See more information on Kineta dividends here
What is Kineta’s EPS estimate?
Kineta’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kineta have?
Kineta has 51,099,000 shares outstanding.
What happened to Kineta’s price movement after its last earnings report?
Kineta reported an EPS of -$0.204 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Kineta?
Currently, no hedge funds are holding shares in KANT
Company Description
Kineta
Proteostasis Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It engages in the discovery and development of novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company was founded by William Balch, Jeffery W. Kelly, Andrew Dillin, Richard I. Morimoto, Alfred Lewis Goldberg, Daniel Finley, Christopher T. Walsh, and Randall W. King in 2006 and is headquartered in Boston, MA.
Technical Analysis
Biodexa Pharmaceuticals
―
Kazia Therapeutics
―
Xenetic Biosciences
―
NLS Pharmaceutics
―
Pasithea Therapeutics Corp
―